A research team led by Tezpur University has identified promising blood-based markers that could enable earlier detection of gallbladder cancer among high-risk gallstone disease patients. Importantly, the study reports distinct blood “metabolic signatures” that differentiate gallbladder cancer occurring with gallstones from cases without gallstones.
Study Published in International Journal
The findings, published this month in the American Chemical Society’s Journal of Proteome Research, highlight specific blood metabolites that may support early diagnosis of gallbladder cancer—an aggressive malignancy that is often detected at an advanced stage.
The study was led by Dr Pankaj Barah, Assistant Professor, and research scholar Dr Cinmoyee Baruah from the Department of Molecular Biology and Biotechnology, Tezpur University.
Clear Metabolic Differences Identified
Explaining the significance of the findings, Dr Barah stated that changes in certain blood chemicals, known as metabolites, can clearly distinguish gallbladder cancer cases with and without gallstones. He further emphasized that simple blood-based tests could aid earlier detection, although additional validation studies and clinical trials will form the next phase of research.
First-of-Its-Kind Study from Northeast India
Notably, this pilot study is the first of its kind from northeast India. The researchers analysed blood samples from three distinct groups: patients with gallbladder cancer without gallstones, patients with gallbladder cancer and gallstones, and individuals with gallstones but no cancer.
Using advanced metabolomics techniques, the team identified hundreds of altered metabolites. Among these, they detected 12 metabolite biomarkers specific to gallstone-free cancer cases, 20 biomarkers linked to gallstone-associated cancer cases, and 30 metabolites common to both groups. According to Dr Baruah, these biomarkers could help identify individuals at a higher risk of developing gallbladder cancer.
Strong Interdisciplinary and Global Collaboration
As reported by TOI, the study involved close collaboration among surgeons, pathologists, pharmaceutical scientists, molecular biologists, and computational scientists. Clinical support came from Assam Medical College and Hospital, Dibrugarh; Dr B Borooah Cancer Institute, Guwahati; and Swagat Super-Speciality Hospital. In addition, analytical and computational expertise was provided by the University of Illinois, Urbana–Champaign (USA), and the CSIR–Indian Institute of Toxicology Research, Lucknow.
Bridging Laboratory Research and Clinical Practice
Commenting on the clinical relevance, Dr Gayatri Gogoi, Pathologist at Assam Medical College, noted that linking tissue pathology with blood metabolomics helps bridge the gap between laboratory research and clinical diagnosis. Similarly, Dr Subhash Khanna, a gastrointestinal surgeon from Guwahati, stated that identifying blood-based metabolic markers offers a practical pathway toward early diagnosis and better clinical decision-making.
Implications for High-Risk Regions
While researchers stressed the need for larger, multi-centre studies before clinical implementation, they emphasized that the findings could support the development of non-invasive screening tools. This is particularly relevant for high-risk regions such as the northeast.
Rising Burden of Gallbladder Cancer
Gallbladder cancer remains one of the deadliest gastrointestinal cancers and shows a disproportionately high incidence in northeast India, where it ranks as the third most common cancer. The disease often progresses silently, leading to late-stage diagnosis. Although gallstones are a well-known risk factor, not all individuals with gallstones develop cancer, and many patients present without any history of gallstones. With projections indicating a rising burden of gallbladder cancer in Assam, the study underscores the urgent need for effective early detection strategies.